Chemotherapy
Anticancer Section / Original Paper
Expression of Activating Protein 4 and Its Relationships with Prognosis in Gastric CancerSun X.a · Feng Z.a · Qu Y.a · Shao J.a · Wei N.baDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, and bDepartment of Oncology, the People's Hospital of Liaoning Province, Shenyang, China
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: September 13, 2016
Accepted: November 30, 2016
Published online: March 24, 2017
Issue release date: April 2017
Number of Print Pages: 6
Number of Figures: 2
Number of Tables: 1
ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)
For additional information: https://www.karger.com/CHE
Abstract
Objective: The aim of this work was to investigate the expression of transcription activating protein 4 (AP-4) in gastric cancer (GC) and its impacts on prognosis. Methods: The cancer tissues and normal tissues of 54 GC patients were sampled for the expression detection of AP-4, and the patients were followed up. Results: The positive expression rate of AP-4 in the cancer tissues (68.5%) was higher than the normal tissues (22.2%; p < 0.01). The lower the tumor differentiation degree and the deeper the invasion depth, the higher the expression rate of AP-4. The median survival time of the patients with positive AP-4 expression was significantly shorter than of those without AP-4 expression (26.3/41.3 months), and the accumulative survival rate of the former was also lower than the latter (χ2 = 4.736, p = 0.03). AP-4 was expressed in GC tissues and normal gastric tissues, with the expression in the former being higher. Conclusions: The expression of AP-4 was positively related with the tumor differentiation degree, invasion depth, lymph node metastasis, and pTNM stage, while it was not related with patient gender, age, tumor size, location, or distant metastasis. AP-4 might be used as an indicator for the prognosis prediction of GC.
© 2017 S. Karger AG, Basel
Related Articles:
References
- Correia M, Machado JC, Ristimaki A: Basic aspects of gastric cancer. Helicobacter 2009;14(suppl 1):36-40.
- Wang W, Huang J, Tao Y, Lyu X, Yang L, Wu D, Tian Y: Phase II and UGT1A1 polymorphism study of two different irinotecan dosages combined with cisplatin as first-line therapy for advanced gastric cancer. Chemotherapy 2016;61:197-203.
- Wu K, Nie Y, Guo C, Chen Y, Ding J, Fan D: Molecular basis of therapeutic approaches to gastric cancer. J Gastroenterol Hepatol 2009;24:37-41.
- Zhang LH, Ji JF: Prognostic biomarkers and targeted therapies for gastric cancer (in Chinese). Zhonghua Wei Chang Wai Ke Za Zhi 2013;16:193-196.
- Jackstadt R, Röh S, Neumann J, Jung P, Hoffmann R, Horst D, Berens C, Bornkamm GW, Kirchner T, Menssen A, Hermeking H: AP4 is a mediator of epithelial-mesenchymal transition and metastasis in colorectal cancer. J Exp Med 2013;210:1331-1350.
- Ross BH, Lin Y, Corales EA, Burgos PV, Mardones GA: Structural and functional characterization of cargo-binding sites on the μ4-subunit of adaptor protein complex 4. PLoS One 2014;9:405-427.
- Jung P, Hermeking H: The c-MYC-AP4-p21 cascade. Cell Cycle 2009;8:982-989.
- Mermod N, Williams TJ, Tjian R: Enhancer binding factors AP-4 and AP-1 act in concert to activate SV40 late transcription in vitro. Nature 1988;332:557-561.
- Tsujimoto K, Ono T, Sato M, Nishida T, Oguma T, Tadakuma T: Regulation of the expression of caspase-9 by the transcription factor activator protein-4 in glucocorticoid-induced apoptosis. J Biol Chem 2005;280:27638-27644.
- Cao J, Tang M, Li WL, Xie J, Du H, Tang WB, Wang H, Chen XW, Xiao H, Li Y: Upregulation of activator protein-4 in human colorectal cancer with metastasis. Int J Surg Pathol 2008;17:16-21.
- Yang S, Zhao Z, Wu R, Lu H, Zhang X, Huan C, Wang C, Wu X, Guan G: Expression and biological relationship of vascular endothelial growth factor-A and matrix metalloproteinase-9 in gastric carcinoma. J Int Med Res 2011;39:2076-2085.
- Gong H, Han S, Yao H, Zhao H, Wang Y: AP4 predicts poor prognosis in nonsmall cell lung cancer. Mol Med Rep 2014;10:336-340.
- Ge Z, Zhang B, Bu X, Wang Y, Xiang L, Tan J: Molecular mechanism of activating protein-4 regulated growth of hepatocellular carcinoma. Tumour Biol 2014;35:12441-12447.
- Liu X, Zhang B, Guo Y, Liang Q, Wu C, Wu L, Tao K, Wang G, Chen J: Down-regulation of AP-4 inhibits proliferation, induces cell cycle arrest and promotes apoptosis in human gastric cancer cells. PLoS One 2012;7:e37096.
- Ziaee S, Chung LW: Induction of integrin α2 in a highly bone metastatic human prostate cancer cell line: roles of RANKL and AR under three-dimensional suspension culture. Mol Cancer 2014;13:1-16.
- Sakurai K, Muguruma K, Nagahara H, Kimura K, Toyokawa T, Amano R, Kubo N, Tanaka H, Ohtani H, Yashiro M, Maeda K, Ohira M, Hirakawa K: The outcome of surgical treatment for elderly patients with gastric carcinoma. J Surg Oncol 2015;111:848-854.
- Murakami H, Nakanishi H, Tanaka H, Ito S, Misawa K, Ito Y, Ikehara Y, Kondo E, Kodera Y: Establishment and characterization of novel gastric signet-ring cell and non signet-ring cell poorly differentiated adenocarcinoma cell lines with low and high malignant potential. Gastric Cancer 2013;16:74-83.
- Yan Y, Wang LF, Wang RF: Role of cancer-associated fibroblasts in invasion and metastasis of gastric cancer. World J Gastroenterol 2015;21:9717-9726.
- Wen R, Gao F, Zhou CJ, Jia YB: Polymorphisms in mucin genes in the development of gastric cancer. World J Gastrointest Oncol 2015;7:328-337.
- Buechler S: Low expression of a few genes indicates good prognosis in estrogen receptor positive breast cancer. BMC Cancer 2009;9:243.
- Xinghua L, Bo Z, Yan G, Lei W, Changyao W, Qi L, Lin Y, Kaixiong T, Guobin W, Jianying C: The overexpression of AP-4 as a prognostic indicator for gastric carcinoma. Med Oncol 2012;29:871-877.
Article / Publication Details
Received: September 13, 2016
Accepted: November 30, 2016
Published online: March 24, 2017
Issue release date: April 2017
Number of Print Pages: 6
Number of Figures: 2
Number of Tables: 1
ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)
For additional information: https://www.karger.com/CHE
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
